CME Group Inc.

Fundamentals8.0
Price Action6.0
News Sentiment7.0
AI Rating
7.0

Key Drivers

  • Margin strength
  • Leverage risk
  • Rich valuation

AI
AI Summary

7.0

CME should now be viewed less as a purely defensive exchange and more as a product-innovation platform with meaningful upside from new contracts and elevated trading volumes, but the stock already prices in strong execution so valuation, regulatory approval, and adoption risk leave limited margin for error.

ProductInnovation
ValuationRisk
RegulatoryRisk‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

8.0

Key Financial Insights:

  • Margin strength
  • Leverage risk
  • Rich valuation

CME shows elite margins and strong cash generation, but elevated leverage, dividend strain, and a rich valuation limit near-term upside.

MarginStrength
LeverageRisk

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Support rebound
  • $290 reclaim
  • $300 resistance

CME's rebound to $298.86 above its last month average and back over $290 is constructive, but choppy trading and resistance near $299-$300 mean it still needs a clean break above $300 to confirm upside.

bullish
watch
Support Level: $285-$286
Resistance Level: $299-$300

Sharp rebound from $281.25 to $298.86, after a prior drop from $290.29 to $281.25, shows choppy but improving momentum

Sentiment & News

7.0

Key News Insights:

  • Record volumes
  • Product expansion
  • Valuation support

CME showed strong operating momentum with record Q1 results and rising volume while aggressively expanding into AI compute, crypto, and uranium-linked products, supporting longer-term growth despite valuation pressure.

Growth
Innovation

The news is broadly positive for CME, signaling durable core strength and new growth avenues that could lift investor sentiment if launches gain regulatory approval